Edwards Lifesciences Corporation
EW Healthcare · Medical DevicesFairly valued.
Fairly Valued (Neutral) — Filing.fyi's reading derived from the latest 10-K and forensic scores.
What the filing actually says.
Edwards Lifesciences Corporation’s most recent 10-Q for the period ended March 31, 2026, is notable for what it explicitly states has not changed. Item 7, Management’s Discussion and Analysis, refers readers to the prior 2025 10-K, asserting no significant changes from the information discussed therein regarding financial condition and results of operations. Similarly, for market risks, the filing states “no material changes” from the prior annual report’s disclosures on interest rate risk, foreign currency risk, credit risk, and concentrations of risk. This brevity suggests a period of relative stability, or at least one without new material developments requiring extensive quarterly elaboration.
The forensic accounting metrics for this filing are uniformly “not available,” which means the Beneish M-Score (Beneish’s 1999 eight-ratio earnings-manipulation detector), Altman Z″ (Altman’s 1968 bankruptcy-distress index), Piotroski F-Score (Piotroski’s 9-point 2000 fundamental strength scan), and Fog Index (Gunning’s 1952 readability score; 12 = newspaper, 18+ = obfuscatory) cannot be assessed from the provided excerpts. While the absence of these scores prevents a quantitative assessment of potential accounting red flags or fundamental strength, it does not, in itself, signal distress. It simply means this particular filing’s excerpts do not provide the necessary data for computation.
Item 1A, Risk Factors, begins with a “NOTE REGARDING FORWARD-LOOKING STATEMENTS,” a common but important section. This note clarifies that the report contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, and that the company intends these statements to be covered by the safe harbor provisions of such Acts. This boilerplate serves as a reminder that any projections or future-oriented comments within the filing are subject to inherent uncertainties and should be interpreted with caution, a standard practice for managing investor expectations.
This filing, therefore, primarily communicates continuity. It tells us that management perceives no material shifts in the company’s financial condition or risk profile since the last annual report. What it cannot tell us, due to the limited excerpts and unavailable forensic scores, is whether there are any subtle accounting trends, underlying financial weaknesses, or strengths that might not be explicitly flagged as “material changes.” A comprehensive view would require the full 10-Q and the referenced 10-K to evaluate the actual financial statements and the detailed risk factors.
Filing timeline
- May 6, 202610-QQuarterly report (2026-03-31)Period: 2026-03-310Read →
- May 4, 20268-KMaterial event (2026-05-02)### Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 0Read →
- Apr 23, 20268-KMaterial event (2026-04-23)No specific items found in 8-K.0Read →
- Mar 26, 2026DEF 14AProxy statement (2026-05-07)0Read →
- Feb 25, 202610-KAnnual report (2025-12-31)Period: 2025-12-310Read →
- Feb 10, 20268-KMaterial event (2026-02-10)No specific items found in 8-K.0Read →
If this case caught your eye
Financial Shenanigans
Schilit's framework for the seven shenanigan types is the standard reference for the kind of MD&A pattern-matching this site does.
View on Amazon →The Interpretation of Financial Statements
The original — and still the clearest — explanation of why working-capital trends matter more than headline earnings.
View on Amazon →Quality of Earnings
Out of print, expensive, worth it. The chapter on receivables-vs-revenue divergence applies almost word-for-word to most distressed filings.
View on Amazon →